Most Read News

On a sequential basis, revenue grew 10.2% from ₹4,292.34 crore, reflecting higher realisations and better volumes during the quarter.

Earnings before interest, tax, depreciation, and amortisation more than doubled to ₹208.5 crore in Q3 FY26 from ₹103 crore reported a year earlier.

The company posted a net profit of ₹323.8 crore for the quarter ended December 2025

The fall in fiscal deficit in December 2025 was more due to front-loading of advance tax receipts

Revenue from operations for the quarter rose 21.2% year on year to ₹15,378.24 crore, compared with ₹12,688.96 crore in Q3 FY25.

According to the Finance Minister, the Bio Pharma Shakti initiative is designed to support research, manufacturing capacity, innovation, and scale across the bio pharma value chain.

While large scale changes in tax rates are unlikely, the markets will look at some smart tweaking of tax rates

Revenue from operations for the quarter slipped 2.7% year on year to ₹34,075.8 crore, down from ₹35,031.2 crore recorded in the year ago period

Earnings before interest, tax, depreciation and amortisation rose 18% year on year to ₹292.5 crore, up from ₹247.7 crore reported in Q3 of the previous financial year.

Indian investors not only want a better investing environment, but also more investment options to choose from